GlobeNewsWire
11 Jan 2026, 23:00 UTC · 35w ago
Verdict
Headline takes no side. We score ESPR +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Esperion's preliminary full-year 2025 U.S. net product sales grew 35% to 38% year-over-year to between $156 million and $160 million.
More positive than 91% of claims this week
Total preliminary revenue for full-year 2025 is estimated between $400 million and $408 million, a 20% to 23% increase over 2024.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 84% of claims this week
Esperion ended 2025 with approximately $168 million in cash and cash equivalents.
So whatProvides visibility into the company's liquidity and its ability to fund the projected 2026 operating expenses.
More positive than 64% of claims this week
The company expects operating expenses for full-year 2026 to be between $210 million and $245 million.
More positive than 44% of claims this week
Esperion introduced 'Vision 2040', a long-term strategy to expand its pipeline into rare hepatic and renal diseases and target a portfolio of at least five marketed products.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported strong full-year 2025 revenue growth, record successful performance, and introduced a bold long-term growth strategy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
22h ago
−18.0%
Price is moving against the score
$3.18 vs $3.88 close before publication (Jan 9) · not market-adjusted
ESPR chart →
